Supplementary materials

Table S1: Characteristics and measurements of patients without RVDN, according to ethnicity.

	Dutch natives n = 238	Turks and Moroccans n = 67	Other ethnic minorities n = 97	P value*
Demographics				
Male gender, n (%)	148 (62)	42 (63)	50 (52)	0.170
Age, median year (range)	66 (60-75)	56 (47-65)	59 (53-71)	**<0.001**
Diabetes duration, median year (IQR)	11 (6-16)	11 (6-16)	10 (5-16)	0.762
Obesity, n (%)	114 (48)	36 (54)	34 (35)	0.027
Current smoking, n (%)	52 (22)	9 (13)	19 (20)	0.329
Current alcohol use, n (%)	132 (55)	2 (3)	27 (28)	**<0.001**
Hemoglobinopathy, n (%)	1 (0)		11 (11)	**<0.001**
Diabetes complications, n (%)				
Nephropathy	136 (57)	33 (49)	42 (43)	0.074
Retinopathy	33 (14)	21 (31)	18 (19)	**0.004**
Neuropathy	61 (26)	10 (15)	6 (6)	**<0.001**
Macrovascular disease	93 (39)	15 (22)	24 (25)	**0.006**
Measurements - median (IQR)				
Systolic BP, mm Hg	128 (117-141)	126 (110-135)	126 (115-137)	0.103
Diastolic BP, mm Hg	75 (69-80)	74 (69-81)	76 (69-81)	0.539
BMI, kg/m^2	30.0 (26.7-33.5)	30.2 (27.6-32.1)	28.1 (25.2-32.3)	**0.026**
Hs-CRP, mg/L	2.05 (0.96-5.09)	1.83 (0.75-5.10)	2.35 (0.59-4.32)	0.621
Hemoglobin, mg/L	8.6 (8.0-9.3)	8.6 (7.9-9.3)	8.5 (7.7-9.1)	0.177
Fasting glucose, mmol/L	7.5 (6.4-8.9)	7.3 (6.2-8.5)	7.1 (6.2-8.3)	0.093
HbA1c, mmol/mol	48 (43-50)	53 (44-57)	51 (45-56)	**0.003**
HbA1c, %	6.5 (6.1-6.7)	7.0 (6.2-7.4)	6.8 (6.3-7.3)	**0.003**
Cholesterol, mmol/L	4.10 (3.59-4.91)	4.01 (3.29-4.54)	4.09 (3.50-4.92)	0.232
HDLc, mmol/L	1.08 (0.88-1.30)	0.96 (0.81-1.06)	1.10 (0.87-1.31)	**0.001**
Triglycerides, mmol/L	1.54 (1.13-2.25)	1.24 (0.85-1.60)	1.23 (0.87-1.75)	**<0.001**
LDLc, mmol/L	2.21 (1.82-2.87)	2.42 (1.93-2.88)	2.35 (1.86-2.97)	0.456
ADA/EASD-targets, n (%)				
HbA1c < 53 mmol/mol	169 (71)	33 (49)	61 (63)	**0.003**
Systolic BP < 130 mm Hg	121 (51)	38 (57)	55 (57)	0.485
Diastolic BP < 80 mm Hg	158 (66)	46 (69)	58 (60)	0.340
HDLc > 1,0 mmol/L	138 (58)	26 (39)	59 (61)	**0.008**
Triglycerides < 1,7 mmol/L	132 (56)	52 (78)	70 (72)	**<0.001**
LDLc < 2,6 mmol/L	163 (69)	40 (60)	61 (63)	0.216

* P-value for differences across the ethnic groups, using χ^2 test for trend (for categorical data) or K-W test (for continuous data).

Table S2: Medication use of patients without RVDN, according to ethnicity.

	Dutch natives n = 238	Turks and Moroccans n = 67	Other ethnic minorities n = 97	P value*
Diabetes treatment, n (%)				
Metformin	217 (91)	64 (96)	90 (93)	0.550
Monotherapy	81 (34)	23 (34)	38 (39)	0.660
Other BG lowering drugs	5 (2)	2 (3)	3 (3)	0.835

Insulin	89 (37)	24 (36)	20 (21)	**0.011**
Twice daily regimen	37 (16)	16 (24)	8 (8)	**0.025**
Intensive regimen	53 (22)	6 (9)	11 (11)	**0.037**
Pump therapy	6 (3)	1 (2)	-	0.481
Daily doses, median (IQR)				
Metformin, grams	1.5 (1.0-2.0)	1.5 (1.0-2.4)	1.7 (1.0-2.0)	0.775
Insulin, units	58 (38-101)	72 (48-86)	58 (34-96)	0.766
Hypertension treatment, n (%)				
ACEi	127 (53)	32 (48)	45 (46)	0.444
ARBs	60 (25)	10 (15)	24 (25)	0.200
Beta blockers	105 (44)	14 (21)	38 (39)	**0.003**
Calcium antagonists	68 (29)	14 (21)	33 (34)	0.188
Diuretics	95 (40)	13 (19)	33 (34)	**0.008**
Other BP lowering drugs	48 (20)	10 (15)	11 (11)	0.131
Number of tablets				
0	29 (12)	21 (31)	18 (19)	**0.001**
1-2	108 (45)	31 (46)	46 (47)	0.943
3-4	79 (33)	13 (19)	27 (28)	0.084
≥5	22 (9)	2 (3)	6 (6)	0.195
Lipid treatment, n (%)				
Statins	158 (66)	44 (66)	64 (66)	0.993
Fibrates	21 (9)	7 (10)	9 (9)	0.920
Ezetimibe	29 (12)	1 (2)	9 (9)	**0.033**

* P-value for differences across the ethnic groups, using χ^2 test for trend (for categorical data) or K-W test (for continuous data).